Neose Technologies, Inc. Announces Closing of Asset Sales to Novo Nordisk A/S and BioGeneriX AG

2009-01-27

合作

HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced the closing on January 27, 2009 of the previously announced sale of substantially all of the Company’s assets to Novo Nordisk A/S (NYSE: NVO) and BioGeneriX AG in accordance with asset purchase agreements dated September 17, 2008 (the “Asset Sales”). The Company received gross proceeds of $43 million in connection with the Asset Sales. Each of the Asset Sales required the approval of Neose stockholders. The required approvals were obtained at a special meeting of stockholders held on January 26, 2009. Morgan Lewis acted as special transaction counsel and RBC Capital Markets acted as exclusive financial advisor to Neose in these transactions.

机构